Company profile
Asceneuron SA
Asceneuron develops effective therapeutics for orphan tauopathies such as progressive supranuclear palsy (PSP) and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Our first candidate molecule for progressive supranuclear palsy is aimed at preventing the formation of toxic tau aggregates by a groundbreaking molecular mechanism and has the potential to enter Phase 1 clinical trials by mid-2015.
Source: startup.ch
More news about Asceneuron SA
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
